EMA Panel Rejects Omeros' Narsoplimab for TA-TMA in Europe — Omeros Corporation

Event summary

CHMP adopts negative opinion on Omeros' MAA for narsoplimab in TA-TMA
Omeros plans to request re-examination and seek review by Ad Hoc Expert Group
Narsoplimab (YARTEMLEA) is FDA-approved but lacks European approval
TA-TMA has high mortality rates, with up to 56% prevalence in allogeneic transplants

The big picture

Omeros faces a significant setback in its efforts to expand narsoplimab's reach into Europe, where TA-TMA remains an unmet medical need. The CHMP's rejection highlights the regulatory hurdles biotech companies encounter when seeking approval for orphan drugs, particularly those with limited clinical trial data. The outcome will test Omeros' ability to navigate European regulatory pathways and sustain its commercial momentum.

What we're watching

Regulatory Reversal: Whether Omeros can overturn the CHMP's negative opinion through re-examination and AHEG review.
Compassionate Use Limits: The extent to which Omeros can provide narsoplimab under compassionate use programs in Europe pending regulatory approval.
Market Differentiation: How the lack of European approval may impact YARTEMLEA's market positioning against potential future competitors.